recombinant mouse il 27 p28 (R&D Systems)

R&D Systems recombinant mouse il 27 p28

FIGURE 1. DNA vaccination-based anti-IL-27 Abs are highly speciﬁc. The Western blot shows that our DNA vaccination-based anti-IL-27 Ab binds mouse IL-27 <t>p28</t> (lane 1; 27 kDa), but not recombinant mouse IL-18, IL-12, or TNF- (lanes 2, 3, and 4, respectively). A, Coomassie Blue staining veriﬁes the appearance of each cytokine on the loaded gel. B, Western blot showing that of these cytokines, our DNA vaccination-based anti-IL-27 Ab binds only mouse IL-27 p28. These Ab also bound natural mouse IL-27 (veriﬁed by sequencing) from supernatant of activated MOGp35–55-speciﬁc cultured primary draining lymph node cells (not shown).

Recombinant Mouse Il 27 P28, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+mouse+il+27+p28/pm15528388-72-1-18?v=R%26D+Systems
Average 92 stars, based on 1 article reviews

recombinant mouse il 27 p28 - by Bioz Stars, 2026-08

92/100 stars

Buy from Supplier

recombinant r murine m il30 (R&D Systems)

R&D Systems recombinant r murine m il30

Figure 1. Expression of <t>IL30</t> and IL30R by PCSLCs, murine, and human prostate tissues. A, Cytoﬂuorimetric analyses of gp130-(CD130) and IL6Ra- (CD126) expression in PIN-SCs. B, Relative expression SD of IL30 mRNA. CTRL, PIN-SCs. ANOVA, P < 0.0001. , P < 0.01, Tukey HSD test compared with CTRL, EV, or EV-IL30shRNA (clones D and B). C, Western blot analyses of IL30 protein expression. D, ELISA assay of IL30 release by CTRL (182.82 6.9 pg/mL), EV-PIN-SCs (168.21 10.82 pg/mL), IL30PIN-SCs (2424.46 83.9 pg/mL), EV-IL30shPIN-SCs (170.44 13.09 pg/mL), and IL30shPIN-SCs (clone D, 6.76 1.87 pg/mL; clone B, 7.53 1.38 pg/mL). ANOVA, P < 0.0001. , P < 0.01, Tukey HSD test compared with CTRL, EV, or EV-IL30shRNA (clones D and B). E, IL30 immunostaining in normal prostate, PIN (11 weeks), and in poorly differentiated tumor (28 weeks) of TRAMP mice. IL30 (brown) colocalizes with Sca-1 (red) in PIN; scale bars, 50 mm (left two); 30 mm (right two and inset). F, Expression of IL6Ra and gp130 in PIN and in poorly differentiated adenocarcinoma (AC) of TRAMP mice; scale bars, 50 mm (left two); 30 mm (right two). G, IL30 immunostaining in normal prostate, PIN (IL30/CD133 colocalization), and in poorly differentiated adenocarcinoma; scale bars, 20 mm (left two and inset); 30 mm (right two).

Recombinant R Murine M Il30, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+mouse+il+27+p28/10__1158_slash_0008___5472__can___17___3117-54-0-9?v=R%26D+Systems
Average 93 stars, based on 1 article reviews

recombinant r murine m il30 - by Bioz Stars, 2026-08

93/100 stars

Buy from Supplier

mouse l 27 p28 il 30 (R&D Systems)

R&D Systems mouse l 27 p28 il 30

Mouse L 27 P28 Il 30, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+mouse+il+27+p28/pm36241161-66-85-88?v=R%26D+Systems
Average 92 stars, based on 1 article reviews

mouse l 27 p28 il 30 - by Bioz Stars, 2026-08

92/100 stars

Buy from Supplier

mouse il 27 (R&D Systems)

R&D Systems mouse il 27

Mouse Il 27, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+mouse+il+27+p28/pm25862525-87-10-12?v=R%26D+Systems
Average 93 stars, based on 1 article reviews

mouse il 27 - by Bioz Stars, 2026-08

93/100 stars

Buy from Supplier

recombinant mouse il 27 p28 il 30 protein (R&D Systems)

N/A

The Recombinant Mouse IL 27 p28 IL 30 Protein from R D Systems is derived from NS0 The Recombinant Mouse IL 27 p28 IL 30 Protein has been validated for the following applications Bioactivity

Buy from Supplier

recombinant mouse il 27 p28 il 30 protein cf (R&D Systems)

N/A

The Recombinant Mouse IL 27 p28 IL 30 Protein from R D Systems is derived from NS0 The Recombinant Mouse IL 27 p28 IL 30 Protein has been validated for the following applications Bioactivity

Buy from Supplier

il-27/p28 mouse recombinant protein (Rockland Immunochemicals)

N/A

IL-27/p28 Mouse Recombinant Protein - 010-001-B54-0.1

Buy from Supplier

recombinant mouse interleukin-27/p28 (il-30) (RayBiotech)

N/A

Recombinant Mouse Interleukin-27/p28 (IL-30); 10 ug

Buy from Supplier

Image Search Results

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Suppression of ongoing experimental autoimmune encephalomyelitis by neutralizing the function of the p28 subunit of IL-27.

doi: 10.4049/jimmunol.173.10.6465

Figure Lengend Snippet: FIGURE 1. DNA vaccination-based anti-IL-27 Abs are highly speciﬁc. The Western blot shows that our DNA vaccination-based anti-IL-27 Ab binds mouse IL-27 p28 (lane 1; 27 kDa), but not recombinant mouse IL-18, IL-12, or TNF- (lanes 2, 3, and 4, respectively). A, Coomassie Blue staining veriﬁes the appearance of each cytokine on the loaded gel. B, Western blot showing that of these cytokines, our DNA vaccination-based anti-IL-27 Ab binds only mouse IL-27 p28. These Ab also bound natural mouse IL-27 (veriﬁed by sequencing) from supernatant of activated MOGp35–55-speciﬁc cultured primary draining lymph node cells (not shown).

Article Snippet: Our recombinant mouse IL-27 p28, produced as described above, and commercially available recombinant mouse IL-18, IL-12, and TNF- (R&D Systems) were each subjected to Western blot analysis according to the protocol described in detail previously (29, 32), with the minor modification of using a 12% (rather than 8%) running gel.

Techniques: Western Blot, Recombinant, Staining, Sequencing, Cell Culture

FIGURE 2. Anti-p28 Abs suppresses ongoing severe EAE. A, Four groups of 10 mice each were subjected to MOGp35–55-induced EAE. Beginning at the onset of disease (day 17), these mice were repeatedly (every other day) administered 100 g/mouse of anti-p28 Ab (f), IgG obtained from naive Lewis rats (Œ), or PBS (E). An observer blind to the experimental procedure scored EAE daily. The experiment summarized in Fig. 2 shows the results of one of three experiments performed under similar experimental conditions, with similar results. The mean maximal score SE represents six mice per group. The other four mice were killed on day 30 and subjected to histological evaluation (see Fig. 3). B, Five groups of six mice each were subjected to MOGp35–55-induced EAE. Beginning at the onset of disease (day 17), these mice were repeatedly (every other day) administered 100 g of anti-p28 Ab/mouse (f), anti-IL-18 Ab (F), anti-IL-1 Ab (), IgG obtained from Lewis rats previously subjected to an empty plasmid administration (Œ), or PBS (E). An observer blind to the experimental procedure scored EAE daily. Results are shown as the mean maximal score SE of six mice per group. C, Three groups of six mice each were subjected to induction of transferred EAE. Beginning at the onset of disease (day 5), these mice were repeatedly (every other day) administered 100 g of anti-p28 Ab/mouse (f), IgG obtained from naive Lewis rats (Œ), or PBS (E). An observer blind to the experimental procedure scored EAE daily. Results are shown as mean maximal score SE of six mice per group.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Suppression of ongoing experimental autoimmune encephalomyelitis by neutralizing the function of the p28 subunit of IL-27.

doi: 10.4049/jimmunol.173.10.6465

Figure Lengend Snippet: FIGURE 2. Anti-p28 Abs suppresses ongoing severe EAE. A, Four groups of 10 mice each were subjected to MOGp35–55-induced EAE. Beginning at the onset of disease (day 17), these mice were repeatedly (every other day) administered 100 g/mouse of anti-p28 Ab (f), IgG obtained from naive Lewis rats (Œ), or PBS (E). An observer blind to the experimental procedure scored EAE daily. The experiment summarized in Fig. 2 shows the results of one of three experiments performed under similar experimental conditions, with similar results. The mean maximal score SE represents six mice per group. The other four mice were killed on day 30 and subjected to histological evaluation (see Fig. 3). B, Five groups of six mice each were subjected to MOGp35–55-induced EAE. Beginning at the onset of disease (day 17), these mice were repeatedly (every other day) administered 100 g of anti-p28 Ab/mouse (f), anti-IL-18 Ab (F), anti-IL-1 Ab (), IgG obtained from Lewis rats previously subjected to an empty plasmid administration (Œ), or PBS (E). An observer blind to the experimental procedure scored EAE daily. Results are shown as the mean maximal score SE of six mice per group. C, Three groups of six mice each were subjected to induction of transferred EAE. Beginning at the onset of disease (day 5), these mice were repeatedly (every other day) administered 100 g of anti-p28 Ab/mouse (f), IgG obtained from naive Lewis rats (Œ), or PBS (E). An observer blind to the experimental procedure scored EAE daily. Results are shown as mean maximal score SE of six mice per group.

Techniques: Plasmid Preparation

FIGURE 4. The beneﬁcial effect of anti-IL-27 is dependent on the con- tinuing administration of protective Abs. Three groups of six mice each were subjected to active induction of EAE. Beginning 1 day after the onset of disease (day 17), these mice were treated with either a single dose of anti-p28 Ab (100 g/mouse; E) or with repeated administration (every other day) of this Ab (Œ) or PBS (f). An observer blind to the experi- mental procedure scored EAE daily. Results are shown as the mean max- imal score SE of six mice per group.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Suppression of ongoing experimental autoimmune encephalomyelitis by neutralizing the function of the p28 subunit of IL-27.

doi: 10.4049/jimmunol.173.10.6465

Figure Lengend Snippet: FIGURE 4. The beneﬁcial effect of anti-IL-27 is dependent on the con- tinuing administration of protective Abs. Three groups of six mice each were subjected to active induction of EAE. Beginning 1 day after the onset of disease (day 17), these mice were treated with either a single dose of anti-p28 Ab (100 g/mouse; E) or with repeated administration (every other day) of this Ab (Œ) or PBS (f). An observer blind to the experi- mental procedure scored EAE daily. Results are shown as the mean max- imal score SE of six mice per group.

Techniques:

FIGURE 3. Anti-IL-27 therapy reduces the histological score of EAE. Histological evaluation was conducted 30 days after disease induction. Lumbar spinal cord samples from naive mice or from EAE mice treated with PBS, IgG from naive mice, or anti-IL-27 p28 Abs were subjected to histological analysis (nine sections each group). The arrowheads point to the parenchymal mononuclear cell inﬁltration. The scale for mononuclear cell inﬁltration used was: 0, no mononuclear cell inﬁltration; 1, one to ﬁve perivascular lesions per section with minimal parenchymal inﬁltration; 2, ﬁve to 10 perivascular lesions per section with parenchymal inﬁltration; and 3, 10 perivascular lesions per section with extensive parenchymal inﬁltration. The mean histological score SE was calculated for each group.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Suppression of ongoing experimental autoimmune encephalomyelitis by neutralizing the function of the p28 subunit of IL-27.

doi: 10.4049/jimmunol.173.10.6465

Figure Lengend Snippet: FIGURE 3. Anti-IL-27 therapy reduces the histological score of EAE. Histological evaluation was conducted 30 days after disease induction. Lumbar spinal cord samples from naive mice or from EAE mice treated with PBS, IgG from naive mice, or anti-IL-27 p28 Abs were subjected to histological analysis (nine sections each group). The arrowheads point to the parenchymal mononuclear cell inﬁltration. The scale for mononuclear cell inﬁltration used was: 0, no mononuclear cell inﬁltration; 1, one to ﬁve perivascular lesions per section with minimal parenchymal inﬁltration; 2, ﬁve to 10 perivascular lesions per section with parenchymal inﬁltration; and 3, 10 perivascular lesions per section with extensive parenchymal inﬁltration. The mean histological score SE was calculated for each group.

Techniques:

FIGURE 5. Protective administration of anti-IL-27 Abs decreases in vivo polarization of CD4 T cells into Th1 and suppresses IFN- production by Ag-speciﬁc T cells. C57BL/6 mice (three per group) were subjected to active induction of EAE and then to repeated administration (days 12, 14, and 16) of anti-IL-27 p28 Abs (100 g), PBS, or normal rat IgG. On day 17 cervical lymph node cells (that drain the autoimmune site) were subjected to intracellular staining of IL-4 and IFN-. A, FACS analysis of CD4 T cells in this experiment. This experiment represents results obtained in three different independent experiments with very similar data. Subsequently, cervical lymph node T cells from these mice were cultured in the presence of 100 M MOGp35–55. After 72 h of stimulation, supernatants were assayed for the protein level of IFN- (B) and IL-4 (not shown). This experiment represents results obtained in three different independent experiments with very similar data.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Suppression of ongoing experimental autoimmune encephalomyelitis by neutralizing the function of the p28 subunit of IL-27.

doi: 10.4049/jimmunol.173.10.6465

Figure Lengend Snippet: FIGURE 5. Protective administration of anti-IL-27 Abs decreases in vivo polarization of CD4 T cells into Th1 and suppresses IFN- production by Ag-speciﬁc T cells. C57BL/6 mice (three per group) were subjected to active induction of EAE and then to repeated administration (days 12, 14, and 16) of anti-IL-27 p28 Abs (100 g), PBS, or normal rat IgG. On day 17 cervical lymph node cells (that drain the autoimmune site) were subjected to intracellular staining of IL-4 and IFN-. A, FACS analysis of CD4 T cells in this experiment. This experiment represents results obtained in three different independent experiments with very similar data. Subsequently, cervical lymph node T cells from these mice were cultured in the presence of 100 M MOGp35–55. After 72 h of stimulation, supernatants were assayed for the protein level of IFN- (B) and IL-4 (not shown). This experiment represents results obtained in three different independent experiments with very similar data.

Techniques: In Vivo, Staining, Cell Culture

FIGURE 6. Neutralizing the function of IL-27 reduces IFN- produc- tion by IFN--producing T cells. A, C57BL/6 mice (three per group) were subjected to active induction of EAE and then to repeated administration (days 3 and 6) of 100 g of anti-IL-27 p28 Abs (group 3), PBS (group 2), or normal rat IgG (group 1). On day 9, spleen cells were subjected to spot ELISA as previously described (38). A, Relative number of positive spots per 107 cultured cells. The average size of positive spots was analyzed. B, The MOGp33–55-speciﬁc CD4 T cell line was cultured with or without 100 M MOGp33–55. Cultured cells were supplemented with anti-IL-27 Abs at a ﬁnal concentration of 10 g/ml (), normal rat IgG (f), or PBS (E). After 60 h of incubation, cells were plates in spot ELISA plates for an additional 24 h for the detection of IFN--positive spots (38). Number of positive spots (y-axis) and spot sizes (x-axis; logarithmic scale) determined as previously described (46).

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Suppression of ongoing experimental autoimmune encephalomyelitis by neutralizing the function of the p28 subunit of IL-27.

doi: 10.4049/jimmunol.173.10.6465

Figure Lengend Snippet: FIGURE 6. Neutralizing the function of IL-27 reduces IFN- produc- tion by IFN--producing T cells. A, C57BL/6 mice (three per group) were subjected to active induction of EAE and then to repeated administration (days 3 and 6) of 100 g of anti-IL-27 p28 Abs (group 3), PBS (group 2), or normal rat IgG (group 1). On day 9, spleen cells were subjected to spot ELISA as previously described (38). A, Relative number of positive spots per 107 cultured cells. The average size of positive spots was analyzed. B, The MOGp33–55-speciﬁc CD4 T cell line was cultured with or without 100 M MOGp33–55. Cultured cells were supplemented with anti-IL-27 Abs at a ﬁnal concentration of 10 g/ml (), normal rat IgG (f), or PBS (E). After 60 h of incubation, cells were plates in spot ELISA plates for an additional 24 h for the detection of IFN--positive spots (38). Number of positive spots (y-axis) and spot sizes (x-axis; logarithmic scale) determined as previously described (46).

Techniques: Enzyme-linked Immunosorbent Assay, Cell Culture, Concentration Assay, Incubation

Figure 1. Expression of IL30 and IL30R by PCSLCs, murine, and human prostate tissues. A, Cytoﬂuorimetric analyses of gp130-(CD130) and IL6Ra- (CD126) expression in PIN-SCs. B, Relative expression SD of IL30 mRNA. CTRL, PIN-SCs. ANOVA, P < 0.0001. , P < 0.01, Tukey HSD test compared with CTRL, EV, or EV-IL30shRNA (clones D and B). C, Western blot analyses of IL30 protein expression. D, ELISA assay of IL30 release by CTRL (182.82 6.9 pg/mL), EV-PIN-SCs (168.21 10.82 pg/mL), IL30PIN-SCs (2424.46 83.9 pg/mL), EV-IL30shPIN-SCs (170.44 13.09 pg/mL), and IL30shPIN-SCs (clone D, 6.76 1.87 pg/mL; clone B, 7.53 1.38 pg/mL). ANOVA, P < 0.0001. , P < 0.01, Tukey HSD test compared with CTRL, EV, or EV-IL30shRNA (clones D and B). E, IL30 immunostaining in normal prostate, PIN (11 weeks), and in poorly differentiated tumor (28 weeks) of TRAMP mice. IL30 (brown) colocalizes with Sca-1 (red) in PIN; scale bars, 50 mm (left two); 30 mm (right two and inset). F, Expression of IL6Ra and gp130 in PIN and in poorly differentiated adenocarcinoma (AC) of TRAMP mice; scale bars, 50 mm (left two); 30 mm (right two). G, IL30 immunostaining in normal prostate, PIN (IL30/CD133 colocalization), and in poorly differentiated adenocarcinoma; scale bars, 20 mm (left two and inset); 30 mm (right two).

Journal: Cancer Research

Article Title: Interleukin-30/IL27p28 Shapes Prostate Cancer Stem-like Cell Behavior and Is Critical for Tumor Onset and Metastasization

doi: 10.1158/0008-5472.can-17-3117

Figure Lengend Snippet: Figure 1. Expression of IL30 and IL30R by PCSLCs, murine, and human prostate tissues. A, Cytoﬂuorimetric analyses of gp130-(CD130) and IL6Ra- (CD126) expression in PIN-SCs. B, Relative expression SD of IL30 mRNA. CTRL, PIN-SCs. ANOVA, P < 0.0001. , P < 0.01, Tukey HSD test compared with CTRL, EV, or EV-IL30shRNA (clones D and B). C, Western blot analyses of IL30 protein expression. D, ELISA assay of IL30 release by CTRL (182.82 6.9 pg/mL), EV-PIN-SCs (168.21 10.82 pg/mL), IL30PIN-SCs (2424.46 83.9 pg/mL), EV-IL30shPIN-SCs (170.44 13.09 pg/mL), and IL30shPIN-SCs (clone D, 6.76 1.87 pg/mL; clone B, 7.53 1.38 pg/mL). ANOVA, P < 0.0001. , P < 0.01, Tukey HSD test compared with CTRL, EV, or EV-IL30shRNA (clones D and B). E, IL30 immunostaining in normal prostate, PIN (11 weeks), and in poorly differentiated tumor (28 weeks) of TRAMP mice. IL30 (brown) colocalizes with Sca-1 (red) in PIN; scale bars, 50 mm (left two); 30 mm (right two and inset). F, Expression of IL6Ra and gp130 in PIN and in poorly differentiated adenocarcinoma (AC) of TRAMP mice; scale bars, 50 mm (left two); 30 mm (right two). G, IL30 immunostaining in normal prostate, PIN (IL30/CD133 colocalization), and in poorly differentiated adenocarcinoma; scale bars, 20 mm (left two and inset); 30 mm (right two).

Article Snippet: Recombinant (r) murine (m) IL30 (#7430-ML) was purchased from R&D Systems.

Techniques: Expressing, Clone Assay, Western Blot, Enzyme-linked Immunosorbent Assay, Immunostaining

Figure 3. Effects of IL30 overproduction or silencing on subcutaneous PCSLC-derived tumors. A, Histology and immunohistochemistry of IL30PIN-SC and IL30shPIN-SC tumors versus controls; scale bars, 50 mm (bottom); 30 mm (other and inset). B, Immunohistochemical features of IL30PIN-SC and EV-IL30PIN-SC tumors; scale bars, 30 mm; 20 mm (granulocytes). C and D, Immune cells in IL30–overexpressing (C) or IL30-silenced (D) PIN-SC tumors. Results are expressed as mean SD of positive cells/ﬁeld evaluated at 400 (0.180 mm2 ﬁeld) by immunohistochemistry. , values signiﬁcantly (P < 0.05) different from controls. H&E, hematoxylin and eosin.

Journal: Cancer Research

Article Title: Interleukin-30/IL27p28 Shapes Prostate Cancer Stem-like Cell Behavior and Is Critical for Tumor Onset and Metastasization

doi: 10.1158/0008-5472.can-17-3117

Figure Lengend Snippet: Figure 3. Effects of IL30 overproduction or silencing on subcutaneous PCSLC-derived tumors. A, Histology and immunohistochemistry of IL30PIN-SC and IL30shPIN-SC tumors versus controls; scale bars, 50 mm (bottom); 30 mm (other and inset). B, Immunohistochemical features of IL30PIN-SC and EV-IL30PIN-SC tumors; scale bars, 30 mm; 20 mm (granulocytes). C and D, Immune cells in IL30–overexpressing (C) or IL30-silenced (D) PIN-SC tumors. Results are expressed as mean SD of positive cells/ﬁeld evaluated at 400 (0.180 mm2 ﬁeld) by immunohistochemistry. , values signiﬁcantly (P < 0.05) different from controls. H&E, hematoxylin and eosin.

Article Snippet: Recombinant (r) murine (m) IL30 (#7430-ML) was purchased from R&D Systems.

Techniques: Derivative Assay, Immunohistochemistry, Immunohistochemical staining

Figure 4. IL30's ability to regulate gene expression of PCSLCs and PCSLC-derived tumors. A, Fold differences of mRNAs between rIL30–treated and untreated PIN-SCs. A signiﬁcant threshold of 2-fold change in gene expression corresponded to P < 0.001. B, Fold differences of mRNAs between IL30shPIN-SCs and EV- IL30shPIN-SCs. Results from the latter are comparable to those from untransfected cells. A signiﬁcant threshold of 2-fold change in gene expression corresponded to P < 0.001. C–E, Immunohistochemical features of prostate draining LNs, IL30PIN-SC, and EV-IL30PIN-SC orthotopic tumors; scale bars, 30 mm. F, Silencing of STAT1 and STAT3 in PIN-SCs, as conﬁrmed by Western blot. G, Fold differences of mRNAs between Stat1 siRNA- or Stat3 siRNA- or CTRL siRNA-transfected PIN-SCs cultured with rIL30 and untreated CTRL siRNA-transfected PIN-SCs. Results from the latter are comparable with those from untreated and untransfected cells. A signiﬁcant threshold of 2-fold change in gene expression corresponded to P < 0.001. , P < 0.05 by Student t test compared with rIL30–treated CTRL siRNA-transfected PIN-SCs. H, Fold differences of mRNAs between Stat1 siRNA- or Stat3 siRNA-transfected PIN-SCs cultured with rIL30 and rIL30–treated CTRL siRNA-transfected PIN-SCs. A signiﬁcant threshold of 2-fold change in gene expression corresponded to P < 0.001.

Journal: Cancer Research

Article Title: Interleukin-30/IL27p28 Shapes Prostate Cancer Stem-like Cell Behavior and Is Critical for Tumor Onset and Metastasization

doi: 10.1158/0008-5472.can-17-3117

Figure Lengend Snippet: Figure 4. IL30's ability to regulate gene expression of PCSLCs and PCSLC-derived tumors. A, Fold differences of mRNAs between rIL30–treated and untreated PIN-SCs. A signiﬁcant threshold of 2-fold change in gene expression corresponded to P < 0.001. B, Fold differences of mRNAs between IL30shPIN-SCs and EV- IL30shPIN-SCs. Results from the latter are comparable to those from untransfected cells. A signiﬁcant threshold of 2-fold change in gene expression corresponded to P < 0.001. C–E, Immunohistochemical features of prostate draining LNs, IL30PIN-SC, and EV-IL30PIN-SC orthotopic tumors; scale bars, 30 mm. F, Silencing of STAT1 and STAT3 in PIN-SCs, as conﬁrmed by Western blot. G, Fold differences of mRNAs between Stat1 siRNA- or Stat3 siRNA- or CTRL siRNA-transfected PIN-SCs cultured with rIL30 and untreated CTRL siRNA-transfected PIN-SCs. Results from the latter are comparable with those from untreated and untransfected cells. A signiﬁcant threshold of 2-fold change in gene expression corresponded to P < 0.001. , P < 0.05 by Student t test compared with rIL30–treated CTRL siRNA-transfected PIN-SCs. H, Fold differences of mRNAs between Stat1 siRNA- or Stat3 siRNA-transfected PIN-SCs cultured with rIL30 and rIL30–treated CTRL siRNA-transfected PIN-SCs. A signiﬁcant threshold of 2-fold change in gene expression corresponded to P < 0.001.

Article Snippet: Recombinant (r) murine (m) IL30 (#7430-ML) was purchased from R&D Systems.

Techniques: Gene Expression, Derivative Assay, Immunohistochemical staining, Western Blot, Transfection, Cell Culture

Figure 5. IL30 favors PCSLC metastasis to the lungs involving CXCR4/CXCL12 axis. A, Histology and immunohistochemistry of lung metastasis in IL30PIN-SC and EV-IL30PIN-SC tumor bearing mice. Scale bars, 50 mm (bottom); 30 mm (other). B, Expression of CXCR4 and CXCL12 in lung metastasis developed in IL30PIN-SC and EV-IL30PIN-SC tumor-bearing mice; scale bars, 30 mm. C, Migration of IL30–treated PIN-SCs toward CXCL12. Results are expressed as mean SD. ANOVA, P < 0.0001. , Tukey HSD test compared with CTRL and rIL30þAb-CXCR4 (P < 0.05) or EVsup and IL30LV-DNAsupþAb-CXCR4 (P < 0.01). , P < 0.01, Tukey HSD test compared with CTRL, rIL30þAb-CXCR4, EVsup, and IL30LV-DNAsupþAb-CXCR4. , Tukey HSD test compared with CTRL, rIL30þAb-CXCR4, EVsup, and IL30LV- DNAsupþAb-CXCR4 (P < 0.01) or IL30LV-DNAsup (P < 0.05). D, Histology and immunohistochemistry of lung metastasis in mice bearing orthotopic IL30PIN-SC and EV-PIN-SC tumors; scale bars, 50 mm; 30 mm (bottom and insets). E, Immune cells in lung metastasis of mice bearing orthotopic IL30PIN-SC tumors versus controls. Results are expressed as mean SD of positive cells/ﬁeld (400) evaluated by immunohistochemistry. , values signiﬁcantly (P < 0.05) different from values in EV-PIN-SC and PIN-SC tumors. H&E, hematoxylin and eosin.

Journal: Cancer Research

Article Title: Interleukin-30/IL27p28 Shapes Prostate Cancer Stem-like Cell Behavior and Is Critical for Tumor Onset and Metastasization

doi: 10.1158/0008-5472.can-17-3117

Figure Lengend Snippet: Figure 5. IL30 favors PCSLC metastasis to the lungs involving CXCR4/CXCL12 axis. A, Histology and immunohistochemistry of lung metastasis in IL30PIN-SC and EV-IL30PIN-SC tumor bearing mice. Scale bars, 50 mm (bottom); 30 mm (other). B, Expression of CXCR4 and CXCL12 in lung metastasis developed in IL30PIN-SC and EV-IL30PIN-SC tumor-bearing mice; scale bars, 30 mm. C, Migration of IL30–treated PIN-SCs toward CXCL12. Results are expressed as mean SD. ANOVA, P < 0.0001. , Tukey HSD test compared with CTRL and rIL30þAb-CXCR4 (P < 0.05) or EVsup and IL30LV-DNAsupþAb-CXCR4 (P < 0.01). , P < 0.01, Tukey HSD test compared with CTRL, rIL30þAb-CXCR4, EVsup, and IL30LV-DNAsupþAb-CXCR4. , Tukey HSD test compared with CTRL, rIL30þAb-CXCR4, EVsup, and IL30LV- DNAsupþAb-CXCR4 (P < 0.01) or IL30LV-DNAsup (P < 0.05). D, Histology and immunohistochemistry of lung metastasis in mice bearing orthotopic IL30PIN-SC and EV-PIN-SC tumors; scale bars, 50 mm; 30 mm (bottom and insets). E, Immune cells in lung metastasis of mice bearing orthotopic IL30PIN-SC tumors versus controls. Results are expressed as mean SD of positive cells/ﬁeld (400) evaluated by immunohistochemistry. , values signiﬁcantly (P < 0.05) different from values in EV-PIN-SC and PIN-SC tumors. H&E, hematoxylin and eosin.

Article Snippet: Recombinant (r) murine (m) IL30 (#7430-ML) was purchased from R&D Systems.

Techniques: Immunohistochemistry, Expressing, Migration

Figure 6. IL30 promotes PCSLC dissemination in the LNs and bone marrow involving CXCR5/CXCL13 upregulation. A, Histology and immunohistochemistry of IL30PIN-SC orthotopic tumors. Isolated Sca-1þ/IL30þ cells (red arrow) inside the blood vessels; scale bars, 50 mm (left); 20 mm (right). B, Immunohistochemistry of LNs draining IL30PIN-SC or EV-IL30PIN-SC orthotopic tumors. The inset shows CK5/6 staining of the primary tumor. In LNs, CK5/6þ colocalizes with Sca-1; scale bars, 30 mm; 20 mm (bottom). C, Immunohistochemistry of bone marrow from mice bearing IL30PIN-SC and PIN-SC orthotopic tumors; scale bars, 50 mm (top); 30 mm (bottom). D, Migration of IL30–treated PIN-SCs toward CXCL13. Results are expressed as mean SD. ANOVA, P < 0.0001. , Tukey HSD test compared with CTRL and rIL30þAb-CXCR5 (P < 0.05) or EVsup and IL30LV-DNAsupþAb-CXCR5 (P < 0.01). , Tukey HSD test compared with CTRL, rIL30þAb-CXCR5, EVsup, and IL30LV-DNAsupþAb-CXCR5 (P < 0.01) or IL30LV-DNAsup (P < 0.05).

Journal: Cancer Research

Article Title: Interleukin-30/IL27p28 Shapes Prostate Cancer Stem-like Cell Behavior and Is Critical for Tumor Onset and Metastasization

doi: 10.1158/0008-5472.can-17-3117

Figure Lengend Snippet: Figure 6. IL30 promotes PCSLC dissemination in the LNs and bone marrow involving CXCR5/CXCL13 upregulation. A, Histology and immunohistochemistry of IL30PIN-SC orthotopic tumors. Isolated Sca-1þ/IL30þ cells (red arrow) inside the blood vessels; scale bars, 50 mm (left); 20 mm (right). B, Immunohistochemistry of LNs draining IL30PIN-SC or EV-IL30PIN-SC orthotopic tumors. The inset shows CK5/6 staining of the primary tumor. In LNs, CK5/6þ colocalizes with Sca-1; scale bars, 30 mm; 20 mm (bottom). C, Immunohistochemistry of bone marrow from mice bearing IL30PIN-SC and PIN-SC orthotopic tumors; scale bars, 50 mm (top); 30 mm (bottom). D, Migration of IL30–treated PIN-SCs toward CXCL13. Results are expressed as mean SD. ANOVA, P < 0.0001. , Tukey HSD test compared with CTRL and rIL30þAb-CXCR5 (P < 0.05) or EVsup and IL30LV-DNAsupþAb-CXCR5 (P < 0.01). , Tukey HSD test compared with CTRL, rIL30þAb-CXCR5, EVsup, and IL30LV-DNAsupþAb-CXCR5 (P < 0.01) or IL30LV-DNAsup (P < 0.05).

Article Snippet: Recombinant (r) murine (m) IL30 (#7430-ML) was purchased from R&D Systems.

Techniques: Immunohistochemistry, Isolation, Staining, Migration

recombinant mouse il 27 p28 Search Results

Image Search Results